Mobic’s blockbuster potential follows COX-2 bad news

Share this article:
Abbott Laboratories reported sales of its NSAID Mobic jumped 176 percent following Merck's withdrawal of Vioxx from the market and news that studies have linked Celebrex and Bextra to heart risk.
Sales of Mobic nearly tripled to $258 million in the fourth quarter of 2004, exceeding most Wall Street estimates by at least $100 million.
Mobic, originally estimated to be a moderate seller, is now expected to achieve blockbuster status with a potential for $1 billion in sales, Abbott said detailing its fourth quarter earnings this week.
The news also is a boon for Germany's Boehringer Ingelheim, which licensed Mobic to Abbott in a co-marketing agreement. The terms of that agreement are slated to change in April, with more Mobic profits going to Boehringer. 
Share this article:

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.